CN114767702B - Inhibitor for knocking down circXPO1 and application thereof in preparation of glioma treatment drugs - Google Patents
Inhibitor for knocking down circXPO1 and application thereof in preparation of glioma treatment drugs Download PDFInfo
- Publication number
- CN114767702B CN114767702B CN202210406260.3A CN202210406260A CN114767702B CN 114767702 B CN114767702 B CN 114767702B CN 202210406260 A CN202210406260 A CN 202210406260A CN 114767702 B CN114767702 B CN 114767702B
- Authority
- CN
- China
- Prior art keywords
- circxpo1
- glioma
- expression
- cell
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010018338 Glioma Diseases 0.000 title claims abstract description 41
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 239000003112 inhibitor Substances 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title description 5
- 238000002360 preparation method Methods 0.000 title description 4
- 230000000694 effects Effects 0.000 claims abstract description 31
- 208000005017 glioblastoma Diseases 0.000 claims abstract description 27
- 108091027967 Small hairpin RNA Proteins 0.000 claims abstract description 20
- 239000004055 small Interfering RNA Substances 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 108091081021 Sense strand Proteins 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 abstract description 30
- 238000013508 migration Methods 0.000 abstract description 9
- 230000005012 migration Effects 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 8
- 201000008968 osteosarcoma Diseases 0.000 abstract description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 abstract description 2
- 206010060862 Prostate cancer Diseases 0.000 abstract description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 abstract description 2
- 238000011529 RT qPCR Methods 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 16
- 238000001514 detection method Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 230000002018 overexpression Effects 0.000 description 10
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 description 9
- 101150094313 XPO1 gene Proteins 0.000 description 9
- 108700002148 exportin 1 Proteins 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 102100029095 Exportin-1 Human genes 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 108090000638 Ribonuclease R Proteins 0.000 description 6
- 238000003197 gene knockdown Methods 0.000 description 6
- 208000030173 low grade glioma Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 108010087230 Sincalide Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000007480 sanger sequencing Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108091028075 Circular RNA Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 208000029824 high grade glioma Diseases 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 201000011614 malignant glioma Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 101710159080 Aconitate hydratase A Proteins 0.000 description 2
- 101710159078 Aconitate hydratase B Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 2
- 101710105008 RNA-binding protein Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000007444 cell Immobilization Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000015909 regulation of biological process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an inhibitor for knocking down circXPO1 and application thereof in preparing a medicament for treating glioma. The expression of the circXPO1 is reported to be related to the occurrence of osteosarcoma, lung adenocarcinoma and prostate cancer, and no related effect on glioblastoma has been reported. According to the invention, a pair of shRNAs are designed according to the splicing sites of the circXPO1, and the shRNAs can obviously inhibit the expression level of the circXPO1 and inhibit the activity, proliferation and migration of glioma.
Description
Technical Field
The invention relates to the technical field of molecular diagnosis, in particular to an inhibitor for knocking down circXPO1 and application thereof in preparing a medicament for treating glioma.
Background
Human gliomas (gliomas) are the most common primary malignant neoplasms in the central nervous system, accounting for 80% of all malignant primary brain and central nervous system tumors. The World Health Organization (WHO) has re-classified gliomas into types I-IV based on histological morphology and molecular characteristics, wherein types I and II are often referred to as Low-grade glioma (LGG), and types III and IV include Glioblastoma (GBM), anaplastic astrocytoma, and anaplastic oligodendroglioma. Gliomas of type III and IV are often considered subjects because of their great tolerance to drugs, high recurrence rate and severe impact on the quality of life of the patient, and correspondingly, greatly shortened survival time. The low-grade glioma has lower incidence rate, only accounts for 15% of the total glioma, and has better treatment effects in clinical treatment methods such as excision, radiotherapy, chemical drug treatment and the like, and has better prognosis, and the patients with more than ten years of survival time account for about 47%. Malignant gliomas are one of the brain tumors with extremely high malignancy, and although the incidence rate of the total population is only 5.55/10 ten thousand, the survival rate of patients is only one third, the survival time of non-interfered patients is only three months, the survival time after treatment is 12-15 months, and the maximum time is no more than five years.
Circular RNAs (circrnas) are a class of covalently closed circular coding RNAs produced by reverse splicing of mRNA precursors, without 3 'polyadenylation tails and 5' cap structures, are generally more stable than their cognate linear mrnas, are not affected by exonucleases, and are expressed with time and tissue specificity, and thus good biomarker candidates. The circrnas fall into three categories: exon circRNA (ecircRNA), formed by reverse splicing of one or more exons; intron circRNA (ciRNA), formed from introns; exon-intron circRNA (EIciRNA) includes both exons and introns. Circrnas are differentially expressed in a variety of diseases and are involved in the regulation of physiological and pathophysiological processes. The CircRNAs mainly prevent downstream target genes from being degraded by miRNA through binding miRNA, bind to RNA Binding Protein (RBP), or regulate transcription and translation of peptides and proteins through RNA-POL II, and participate in central nervous system related diseases, tumors and other processes. The research of the generation and the function of the circRNA relates to aspects of the tumor fields such as lung cancer, breast cancer, osteosarcoma, glioma and the like. Thus, circRNA can be used as a means for treating tumors, and further promotes the development of the related field.
The expression of the circXPO1 is reported to be related to the occurrence of osteosarcoma, lung adenocarcinoma and prostate cancer, and no related effect on glioblastoma has been reported. Through long-term research, the inhibitor of the circXPO1 can be used as an active substance and has a certain therapeutic effect on malignant glioma.
Disclosure of Invention
The first object of the invention is to provide an application of shRNA with knockdown circXPO1 in preparing a medicine or health care product for treating glioma, wherein the nucleotide sequence of the shRNA consists of a sense strand and an antisense strand:
the nucleotide sequence of the sense strand is shown in SEQ ID NO. 2: 5'-GATCCGTGCGAAGTAATCTATGCCAGCCTTCCTGTCAGAGCTGGCATAGA TTACTTCGCACTTTTTG-3';
the nucleotide sequence of the antisense strand is shown in SEQ ID NO. 3: 5'-AATTCAAAAAGTGCGAAGTAATCTATGCCAGCTCTGACAGGAAGGCTGG CATAGATTACTTCGCACG-3'.
The nucleotide sequence of the circXPO1 gene is shown as SEQ ID NO. 1.
Preferably, the glioma is glioma cell U-87MG or glioma cell U251.
The second object of the invention is to provide an application of shRNA with knockdown circXPO1 in preparing glioblastoma activity inhibitor.
A third object of the present invention is to provide a medicament for treating glioma comprising shRNA with knockdown circXPO 1.
Preferably, the dosage form of the medicament is any one of the dosage forms approved in medicine.
Preferably, a pharmaceutically acceptable carrier is also included.
The fourth object of the invention is to provide an inhibitor shRNA for knocking out the circXPO1, which can inhibit the growth of glioma under the condition of interfering the expression of the circXPO1, and provides a new solution for clinically treating glioma. The inhibitor inhibits the expression of circXPO1 to reduce the level of the expression product of circXPO 1.
In order to explore the role of circXPO1 in glioma occurrence and development, a pair of shRNAs are designed according to the splicing site of the circXPO1, and the shRNAs and scrambles (negative control) are infected by a slow virus packaging method by using a transfection reagent to knock down the expression of the circXPO1 by using a U87-MG and U251 cell line. Cells are collected after 72 hours of infection, and the expression level of the circXPO1 is detected by using a real-time fluorescent quantitative PCR technology to detect the transfection efficiency of shRNA, so that the designed shRNA can obviously inhibit the expression level of the circXPO1 and can inhibit the activity, proliferation and migration of glioma. Meanwhile, the overexpression of the circXPO1 can promote the cell activity, proliferation, migration and the like of glioma, so that the circXPO1 has important significance for treating glioma.
Drawings
FIG. 1 shows the circular structure of circXPO1 and Sanger sequencing; (A) the cyclic structure of circXPO1 and the formation of a schematic diagram, (B) the peak diagram of the sanger sequencing result, (C) RT-PCR detection of the cyclic structure of circXPO1 and the specificity of the primer, (D) qRT-PCR detection of the expression level of circXPO1 after RNase R treatment, and (E) qRT-PCR detection of the expression level of XPO1 after RNase R treatment.
FIG. 2 shows the expression levels of circXPO1 in normal and glioma tissues and GBM cell lines; (A) qRT-qPCR detection of the expression level of circXPO1 in Normal brain tissue (Normal), low Grade Glioma (LGG) and high grade Glioma (GBM), and (B) qRT-qPCR detection of the expression level of circXPO1 in U87-MG cells and U251 cells.
FIG. 3 shows qRT-PCR detection of the knockdown efficiency of shRNA of circXPO1 in glioma cell lines; (A) The expression level of the circXPO1 after the circXPO1-sh treatment was changed, and the expression level of the XPO1 after the circXPO1-sh treatment was changed.
FIG. 4 shows the effect of CCK-8 detection of the circXPO1-sh treatment on the activity of U87-MG and U251 cells.
FIG. 5 shows the effect of immunofluorescence detection of the cell proliferation of U87-MG and U251 after the circXPO1-sh treatment.
FIG. 6 is a graph showing the effect of scratch assay on the ability of U87-MG and U251 cells to heal after treatment with circXPO 1-sh.
FIG. 7 shows qRT-PCR detection of the overexpression efficiency of circXPO1 in glioma cell lines.
FIG. 8 is the effect on U87-MG and U251 cell growth, proliferation and migration after overexpression of circXPO 1; (A) is the effect of CCK-8 on the cell viability of U87-MG and U251 after the overexpression of circXPO1, (B) is the effect of immunofluorescence on the proliferation of U87-MG and U251 after the overexpression of circXPO1, and (C) is the effect of the cell scratch healing ability of U87-MG and U251 after the overexpression of circXPO 1.
Detailed Description
The invention is further described below in connection with specific embodiments, but the scope of the invention is not limited thereto.
Example 1: sanger sequencing and RNase R treatment demonstrated that circular RNA was formed
1. Experimental method
1. RT-PCR to obtain circXPO1
Total RNA from GBM cell lines (i.e., U87-MG, U251 cells) was extracted and reverse transcribed using Trizol reagent (Thermo Fisher Scientific) for RT-PCR analysis. The primers are shown in (Table 1).
To demonstrate that the circXPO1 formation is circular RNA rather than linear, RT-PCR products were recovered, sent to the company for sanger sequencing, and the sequencing results were aligned using DNASTAR software. The results showed that circXPO1 is indeed formed by head-to-tail cyclization of exons 2, 3 and 4 of the parent gene XPO1 (FIG. 1A, B, C).
2. To confirm the cyclic structure of circXPO1, the stability was assessed by treatment with exonuclease (RNase R). The results indicated that circXPO1 is resistant to RNase R (FIG. 1D), whereas XPO1 is digested by RNase R degradation (FIG. 1E). In summary, circXPO1 is a cyclic and stable transcript.
TABLE 1 PCR and qPCR primer sequences for circXPO1 and XPO1
Example 2: expression of circXPO1 in normal and glioma tissues and GBM cell lines
1. The experimental method comprises the following steps:
1. fluorescent quantitative PCR detection of expression of circXPO1 in normal tissues and glioma tissues and GBM cell lines
Total RNA of glioma tissues and GBM cell lines (i.e., U87-MG, U251 cells) were extracted and Trizol reagent (Thermo Fisher Scientific) was used for fluorescent quantitative PCR (qRT-PCR) analysis. Amplification reactions were performed by a cfx96 real-time PCR detection system (Bio-Rad corporation, hercules, CA, usa) using SYBR Green fluorescent quantitative PCR kit according to the operating specifications. For the circXPO1 and XPO1 primers (Table 1) shown, 2 was used -ΔΔCT The expression of the relevant gene was calculated by the method. All qRT-PCR experiments were repeated three times, all data using GAPDH as a control.
2. Experimental results
The expression of circXPO1 was analyzed in normal brain tissue, low grade glioma tissue samples, high grade glioma tissue samples and related cell lines (U87-MG and U251). qRT-PCR results showed that circXPO1 expression was up-regulated in high grade GBM tissue (FIG. 2A) as well as in several GBM derived cell lines such as U87-MG and U251 (FIG. 2B).
Example 3: inhibition of circXPO1 expression using shRNA in U87-MG and U251 cells
1. Experimental method
1. Construction of scramble, circXPO1-sh plasmid (GFP Co-expression): the most commonly used interfering plasmid construction method was used, and the plasmid was constructed by cleavage of shRNA sequences with the P GreenPuro vector (Bio) using the enzyme endonuclease (Biolabs) and ligation with T4 ligase (Biyun).
The method for obtaining the virus liquid comprises the following steps: (1) 2 1.5mL centrifuge tubes were taken and 30. Mu.LDMEM, 30. Mu. LFectin (ThermoFisher) was added. (2) 2 additional 1.5mL centrifuge tubes were added with 60. Mu.L DEMEM, 0.75. Mu.g pspax2 packaging plasmid, 0.25. Mu.g pmd2.G packaging plasmid, 1. Mu.g scramble, circXPO1-sh interfering plasmid, respectively, then mixed with the solution from the centrifuge tube of step (1), allowed to stand for 20 minutes, then added to 293T cell sap cultured in DMEM medium containing 10% fetal bovine serum, respectively, and after 24 and 48 hours, culture supernatants were taken, respectively.
U87-MG and U251 cells were infected with virus solution with scramble and circXPO1-sh, and subsequent experiments were performed after cell infection efficiency was observed to be 90% or more under a fluorescence microscope.
2. And detecting the high-low effect of the circXPO1-sh by adopting a qRT-PCR method.
Total RNA was obtained from U87-MG and U251 cells after scramble and circXPO1-sh infection, and Trizol reagent (Thermo Fisher Scientific) was used for real-time quantitative PCR (qRT-PCR) analysis. Amplification reactions were performed by a cfx96 real-time PCR detection system (Bio-Rad corporation, hercules, CA, usa) using SYBR Green fluorescent quantitative PCR kit according to the operating specifications. For the circXPO1 and XPO1 referencesThe results are shown in Table 1, use 2 -ΔΔCT The expression of the relevant gene was calculated by the method. All qRT-PCR experiments were repeated three times, all data using GAPDH as a control.
2. Experimental results
And detecting the expression level of the circXPO1 by using qRT-PCR technology to detect the high and low efficiency of shRNA, and confirming that the circXPO1-sh down regulates the expression of the circXPO1, wherein Pvalue is less than 0.05. (see FIG. 4A). Meanwhile, qRT-PCR detection shows that the shiRNA does not knock down the expression of linear XPO1 (see FIG. 4B), which shows that the shRNA specifically knocks down the expression of circXPO 1.
Example 4 Effect of circXPO1 inhibition on GBM cell viability
1. Experimental method
1、CCK-8
After infection of glioma cell lines (U87-MG and U251) with lentiviruses according to method one of example 3, 100. Mu.L of glioma cells were prepared in 2000/Kong Chuanzhi 96-well plates according to (U87-MG and U251) with DMEM medium containing 10% fetal bovine serum. Dividing into a scramble group and a circXPO1-sh group, placing the culture plates in an incubator at 37 ℃ and CO 2 Incubation was performed at 5% concentration for a suitable period of time (0-7 days) and medium was removed from the scramble and circXPO1-sh plates at 1,3,5,7 days and replaced with DMEM medium containing 10% CCK 8. The plates were incubated in the incubator for 1 hour. The absorbance (OD value) at 450nm was measured with a microplate reader.
2. Experimental results
The effect of circXPO1 on GBM cell viability was examined in the GBM cell lines U87-MG and U251, and it was found that the interference of circXPO1-sh significantly inhibited U87-MG and U251 cell viability (FIG. 4A).
EXAMPLE 5 BrdU labelling and Ki-67 staining analysis of the effect of inhibition of circXPO1 on GBM cell proliferation
1. Experimental method
1. BrdU labeling method and Ki-67 staining method
(1) Preparation of cell samples: lentiviral infection of glioma cell lines (U87-MG and U251) according to method one of example 3
(2) BrdU (5-bromodeoxyuridine) was added at a final concentration of 90g/L and incubated at 37℃for 2 hours. After 2 hours incubation of the medium, the medium was discarded and the cells were washed 2 times for 5 minutes in PBS. (3) cell immobilization: mu.l of cell fixative (4% paraformaldehyde) was added to each well and incubated at room temperature for 30 min, and the fixative was discarded. The PBS was washed 3 times for 5 minutes each.
(4) HCl fixation: to each well of the culture well of step 2, 2M aqueous HCl solution was added enough to cover the cells, and after incubation at 37℃for 20 minutes, PBS was washed 3 times for 5 minutes each.
(5) Closing: blocking with 5% sheep serum was performed for 1 hour at room temperature.
(6) Incubating primary antibody and secondary antibody: primary antibodies (mouse BrdU mab and rabbit Ki-67 mab) were incubated overnight at 4 ℃, washed 3 times with PBS, then secondary antibodies (goat-anti-mouse IgG1 (r 1), 594 and goat-anti-rabit IgG, 633) were incubated for 1 hour, DAPI (4', 6-diamidino-2-phenylindole) was added 5 minutes before the end of secondary antibody incubation at a volume ratio of 1:10000, and PBS was washed three times. Photographing under a fluorescence microscope.
2. Experimental results
The effect of circXPO1 on GBM cell proliferation in the GBM cell lines (U87-MG and U251) was examined using the BrdU labeling method and the Ki-67 staining method, and it was found that circXPO1-sh significantly inhibited BrdU positive cells and Ki-67 positive cells in U87-MG and U251 cells, and significantly inhibited proliferation of U87-MG and U251 cells (FIG. 5).
Example 6 influence of circXPO1 interference on GBM cell migration capacity.
1. Experimental method
1. Cell migration experiments
After infection of glioma cell lines (U87-MG and U251) with lentiviruses according to method one of example 3, serum-free medium was changed when cell confluency reached around 80%, and after 24 hours of serum starvation of cells, streaking experiments were performed with a small-size gun head, washing 2 times with PBS to wash off floating cells, and serum-free medium was added.
2. Photographing and observing
The scratch sites were photographed every 24 hours under a microscope and the scratch widths were statistically analyzed.
2. Experimental results
The effect of circXPO1 inhibition on GBM cell migration was studied by a wound healing assay. The circXPO1-sh was found to significantly inhibit migration of U87-MG and U251 cells (FIG. 6).
Example 7 qRT-PCR detection of the overexpression Effect of circXPO1
1. Experimental method
1. Vector plasmid construction
Construction of Vector, circXPO1-OE plasmid (GFP Co-expression): the most commonly used method of construction of overexpressed plasmids was performed by endonuclease (Thermo) cleavage of the pLC5-ciR vector (Gift biosciences) and ligation with T4 ligase (Biyun) to construct the plasmid. The full length sequence of circXPO1 was cloned into the pLC5-ciR plasmid empty.
2. Method for obtaining virus liquid
(1) 2 1.5mL centrifuge tubes were taken and 30. Mu.LDMEM, 30. Mu. LFectin (ThermoFisher) was added. (2) Another 2 1.5mL centrifuge tubes were added with 60. Mu.L DMEM, 0.75. Mu.g pspax2 packaging plasmid, 0.25. Mu.g pmd2.G packaging plasmid, 1. Mu.g Vector, circXPO1-OE plasmid, respectively, then mixed with the solution from the centrifuge tube of step (1), allowed to stand for 20 minutes, then added to 293T cell broth cultured in DMEM medium containing 10% fetal bovine serum, respectively, and after 24 and 48 hours, the culture supernatants were taken, respectively. U87-MG and U251 cells were infected with virus solution with Vector and circXPO1-OE, and subsequent experiments were performed after cell infection efficiencies of 90% or more were observed under a fluorescence microscope.
3. And detecting the overexpression effect of the circXPO1-OE by adopting a qRT-PCR method.
Total RNA was obtained from U87-MG and U251 cells after Vector and circXPO1-OE infection, and Trizol reagent (Thermo Fisher Scientific) was used for real-time quantitative PCR (qRT-PCR) analysis. Amplification reactions were performed by a cfx96 real-time PCR detection system (Bio-Rad corporation, hercules, CA, usa) using SYBR Green fluorescent quantitative PCR kit according to the operating specifications. For the circXPO1 and XPO1 primers as shown in Table 1, 2 was used -ΔΔCT The expression of the relevant gene was calculated by the method. All qRT-PCR experiments were repeated three times, all data using GAPDH as a control.
2. Experimental results
The expression level of the circXPO1 is detected by using qRT-PCR technology to detect the overexpression efficiency of the circXPO1, and the fact that the circXPO1-OE up-regulates the expression of the circXPO1 is confirmed that the Pvalue is smaller than 0.05. (see FIG. 7).
Example 8: effect of overexpression of circXPO1 on GBM cell activity, proliferation and migration capacity.
1. Experimental method
The effect of circXPO1 on GBM cell activity, proliferation and migration capacity was examined according to the methods of examples 4, 5 and 6.
2. Experimental results
The effect of over-expressed circXPO1 on GBM cell activity, proliferation and migration capacity was tested using CCK-8, brdu labeling, ki-67 staining and scratch experiments, and the results showed that over-expressed circXPO1 could significantly increase GBM cell activity as shown in FIG. 8A, promote cell proliferation as shown in FIG. 8B and migration as shown in FIG. 8C.
Sequence listing
<110> Hangzhou university of education
<120> an inhibitor for knocking down circXPO1 and application thereof in preparation of glioma treatment drugs
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 307
<212> RNA
<213> Artificial sequence (circXPO 1)
<400> 1
uaaucuaugc cagcaauuau gacaauguua gcagaccaug cagcucguca gcugcuugau
uucagccaaa aacuggauau caacuuauua gauaaugugg ugaauugcuu auaccaugga
gaaggagccc agcaaagaau ggcucaagaa guacugacac auuuaaagga gcauccugau
gcuuggacaa gagucgacac aauuuuggaa uuuucucaga auaugaauac gaaauacuau
ggacuacaaa uuuuggaaaa ugugauaaaa acaaggugga agauucuucc aaggaaccag
ugcgaag 307
<210> 2
<211> 67
<212> DNA
<213> Artificial sequence (circXPO 1-shRNA sense strand)
<400> 2
gatccgtgcgaagtaatctatgccagccttcctgtcagagctggcatagattacttcgcactttttg 67
<210> 3
<211> 67
<212> DNA
<213> Artificial sequence (circXPO 1-shRNA antisense strand)
<400> 3
aattcaaaaagtgcgaagtaatctatgccagctctgacaggaaggctggcatagattacttcgcacg 67
<210> 4
<211> 22
<212> DNA
<213> Artificial sequence (primer 1)
<400> 4
cagtgcgaag taatctatgc ca 22
<210> 5
<211> 20
<212> DNA
<213> Artificial sequence (primer 2)
<400> 5
gagccattct ttgctgggct 20
<210> 6
<211> 22
<212> DNA
<213> Artificial sequence (primer 3)
<400> 6
agtcgaatgg ctaaaccaga gg 22
<210> 7
<211> 20
<212> DNA
<213> Artificial sequence (primer 4)
<400> 7
ggagcctatt gcccaacaca 20
<210> 8
<211> 20
<212> DNA
<213> Artificial sequence (primer 5)
<400> 8
ccaaggagta agacccctgg 20
<210> 9
<211> 20
<212> DNA
<213> Artificial sequence (primer 6)
<400> 9
tggttgagca cagggtactt 20
Claims (4)
1. The application of shRNA with knockdown circXPO1 in preparing a medicament for treating glioma is characterized in that the nucleotide sequence of the shRNA consists of a sense strand and an antisense strand, the nucleotide sequence of the sense strand is shown as SEQ ID NO.2, and the nucleotide sequence of the antisense strand is shown as SEQ ID NO. 3.
2. The use according to claim 1, wherein the glioma is glioma cell U-87MG or glioma cell U251.
3. The application of shRNA with knockdown circXPO1 in preparing glioblastoma activity inhibitor is characterized in that the nucleotide sequence of shRNA consists of a sense strand and an antisense strand, the nucleotide sequence of the sense strand is shown as SEQ ID NO.2, and the nucleotide sequence of the antisense strand is shown as SEQ ID NO. 3.
4. The use according to claim 3, wherein the glioblastoma is glioma cell U-87MG or glioma cell U251.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210406260.3A CN114767702B (en) | 2022-04-18 | 2022-04-18 | Inhibitor for knocking down circXPO1 and application thereof in preparation of glioma treatment drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210406260.3A CN114767702B (en) | 2022-04-18 | 2022-04-18 | Inhibitor for knocking down circXPO1 and application thereof in preparation of glioma treatment drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114767702A CN114767702A (en) | 2022-07-22 |
CN114767702B true CN114767702B (en) | 2023-06-16 |
Family
ID=82431312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210406260.3A Active CN114767702B (en) | 2022-04-18 | 2022-04-18 | Inhibitor for knocking down circXPO1 and application thereof in preparation of glioma treatment drugs |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114767702B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104725291A (en) * | 2015-02-12 | 2015-06-24 | 领思科技(大连)有限公司 | XPO1 inhibitor |
CN106591428A (en) * | 2016-09-23 | 2017-04-26 | 宁波大学 | Detection and application of new molecular marker hsa-circ-0001017 of gastric cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017055487A2 (en) * | 2015-09-29 | 2017-04-06 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | A METHOD FOR DIAGNOSING A DISEASE BY DETECTION OF circRNA IN BODILY FLUIDS |
-
2022
- 2022-04-18 CN CN202210406260.3A patent/CN114767702B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104725291A (en) * | 2015-02-12 | 2015-06-24 | 领思科技(大连)有限公司 | XPO1 inhibitor |
CN106591428A (en) * | 2016-09-23 | 2017-04-26 | 宁波大学 | Detection and application of new molecular marker hsa-circ-0001017 of gastric cancer |
Also Published As
Publication number | Publication date |
---|---|
CN114767702A (en) | 2022-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | miR-30a negatively regulates TGF-β1–induced epithelial-mesenchymal transition and peritoneal fibrosis by targeting Snai1 | |
WO2021203798A1 (en) | Use of splicing factor prpf31 inhibitor in preparing drug | |
CN108004322B (en) | Application of lncRNA in diagnosis and/or treatment of lung adenocarcinoma | |
CN109321656B (en) | Use of protein DEPDC1 as marker for diagnosing triple-negative breast cancer | |
CN111481672B (en) | Use of agent for inhibiting SGCE gene | |
CN114767702B (en) | Inhibitor for knocking down circXPO1 and application thereof in preparation of glioma treatment drugs | |
CN109512833B (en) | Function and use of E2F6 inhibitors | |
CN110917357A (en) | Application of human GSDMB gene and related product | |
CN110791566A (en) | Application of human SHCBP1 gene and related product | |
CN111020036B (en) | Application of human circ-STXBP5L and related product | |
CN113564252B (en) | New use of methylase METTL3 | |
CN110938691B (en) | Application of human DUS4L gene and related products | |
CN110396544B (en) | Application of CUL7 in glioma diagnosis, treatment and prognosis | |
CN110643707B (en) | ESCC (persistent resonant cell) -related lncRNA LLNLR-299G3.1 and application thereof | |
CN110904104B (en) | Application of human HIST1H2BK gene and related products | |
CN117568476B (en) | Colorectal cancer diagnosis, metastasis prediction and immunotherapy prognosis evaluation circRNA marker and therapeutic drug | |
CN114908160B (en) | SNORD60 as endometrial cancer diagnosis marker and application thereof | |
CN116803424B (en) | SLC17A5 gene inhibitor and application thereof | |
CN112961917B (en) | Use of snoRNA-U35A in the detection and treatment of pancreatic cancer | |
CN110882390B (en) | Application of human LSM5 gene and related product | |
CN116463344B (en) | Method for reducing TOMM22 expression and inhibiting tumor | |
US20150258173A1 (en) | Compositions for modulating invasion ability of a tumor and methods thereof | |
US10835551B2 (en) | Double-stranded nucleic acid molecule, DNA, vector, cancer cell growth inhibitor, cancer cell migration inhibitor, and drug | |
CN109750040B (en) | Application of HEATR1 gene or protein inhibitor in preparation of antitumor drugs | |
CN118236496A (en) | Application of PAX6 in inhibiting neuroendocrine transformation of prostate cancer and enhancing sensitivity of tumor to second-generation endocrine treatment drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |